Tavros Therapeutics

Tavros Therapeutics is creating novel genetically targeted cancer treatments. While mutations give cancers their proliferative potential, it can also render the cells vulnerable to other drugs. This concept is referred to as synthetic lethality. Leveraging functional and computational genomics technologies, Tavros is uncovering the unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need. This involves using Tavros’ bidirectional CRISPR-based synthetic lethality discovery engine. With their platform, Tavros is building a highly innovative pipeline of category-defining small molecule drug candidates.

Jobs: